BioTelemetry Inc. 07.28.16
BioTelemetry Inc., a wireless medical technology company focused on the delivery of health information, has received U.S. Food and Drug Administration (FDA) 510(k) clearance of its next-generation Mobile Cardiac Outpatient Telemetry device, the MCOT Patch. The patch is a four-lead, two-channel system which provides the same technology as the current MCOT, in a more convenient form factor. The MCOT devices, through the use of a proprietary algorithm, offer the most accurate remote arrhythmia detection available on the market, according to BioTelemetry.
The new device was developed in partnership with Belgium-based IMEC, a leading developer of nanoelectronics. The system also incorporates proprietary patch technology the company recently acquired from DELTA Danish Electronics, Light and Acoustic. The company expects the MCOT Patch to be commercially available later this year.
“We are extremely excited to announce this latest milestone in the evolution of our MCOT technology," said Joseph H. Capper, president and CEO of BioTelemetry. "Validated by numerous clinical publications and abstracts, MCOT is widely recognized among remote monitoring options as the 'gold standard' in terms of sensitivity and accuracy in the detection of arrhythmias such as atrial fibrillation. The MCOT Patch incorporates this same unmatched detection capability into a light-weight, easy-to-use patch form factor, which we believe will lead to higher utilization. Moreover, due to its advanced capabilities and flexible design, our new sensor is also anticipated to have commercially viable applications in other areas of healthcare. The introduction of the new system demonstrates our ongoing commitment to reaching as many patients as possible with our life-saving technology and service.”
BioTelemetry Inc., formerly known as CardioNet Inc., provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices, and centralized cardiac core laboratory services. The company is based in Malvern, Pa.
The new device was developed in partnership with Belgium-based IMEC, a leading developer of nanoelectronics. The system also incorporates proprietary patch technology the company recently acquired from DELTA Danish Electronics, Light and Acoustic. The company expects the MCOT Patch to be commercially available later this year.
“We are extremely excited to announce this latest milestone in the evolution of our MCOT technology," said Joseph H. Capper, president and CEO of BioTelemetry. "Validated by numerous clinical publications and abstracts, MCOT is widely recognized among remote monitoring options as the 'gold standard' in terms of sensitivity and accuracy in the detection of arrhythmias such as atrial fibrillation. The MCOT Patch incorporates this same unmatched detection capability into a light-weight, easy-to-use patch form factor, which we believe will lead to higher utilization. Moreover, due to its advanced capabilities and flexible design, our new sensor is also anticipated to have commercially viable applications in other areas of healthcare. The introduction of the new system demonstrates our ongoing commitment to reaching as many patients as possible with our life-saving technology and service.”
BioTelemetry Inc., formerly known as CardioNet Inc., provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices, and centralized cardiac core laboratory services. The company is based in Malvern, Pa.